Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

by Moore, N.F, Azarova, A.M, Bhatnagar, N, Ross, K.N, Drake, L.E, Frumm, S, Liu, Q.S, Christie, A.L, Sanda, T, Chesler, L, Kung, A.L, Gray, N.S, Stegmaier, K, George, R.E
Published 2020

Characterization of notch1 antibodies that inhibit signaling of both normal and mutated notch1 receptors

by Aste-Am閦aga M., Zhang N., Lineberger J.E., Arnold B.A., Toner T.J., Gu M., Huang L., Vitelli S., Vo K.T., Haytko P., Zhao J.Z., Baleydier F., L'Heureux S., Wang H., Gordon W.R., Thoryk E., Andrawes M.B., Tiyanont K., Stegmaier K., Roti G., Ross K.N., Franlin L.L., Wang H., Wang F., Chastain M., Bett A.J., Audoly L.P., Aster J.C., Blacklow S.C., Huber H.E.
Published 2019